

# **The evolving paradigm of hematopoietic stem cells and their derived lineages**

Elisa Laurenti<sup>1,#</sup>, Berthold Göttgens<sup>1,#</sup>

<sup>1</sup>: Department of Haematology and Wellcome Trust and MRC Cambridge Stem Cell

Institute, University of Cambridge, Cambridge UK

<sup>#</sup>: corresponding authors: EL: [el422@cam.ac.uk](mailto:el422@cam.ac.uk); BG: [bg200@cam.ac.uk](mailto:bg200@cam.ac.uk)

## **Preface**

The development of mature blood cells from haematopoietic stem cells (HSCs) has long served as a paradigm for stem cell research, with the haematopoietic differentiation tree used widely as a model for maintenance of hierarchically organised tissues. Recent results and new technologies have challenged the demarcations between stem and progenitor populations, the timing of cell fate choices and the contribution of stem and multipotent progenitor cells to steady-state blood maintenance. These evolving views of haematopoiesis have broad implications for our understanding of adult stem cell function, as well as the development of new therapies for malignant and non-malignant haematopoietic diseases.

## **Introduction**

When Ernst Haeckel first used the word stem cell (Stammzelle) in 1868, as a Darwinist he used it to refer to the primordial unicellular organism from which all multicellular life descended <sup>1</sup>. This stem cell therefore sat at the root of a branching family tree, incidentally called a stem tree in German (Stammbaum, e.g. a tree that shows where things stem from). Haeckel's biogenetic law (ontogeny recapitulates phylogeny) shortly thereafter prompted him to use the stem cell term also to describe the fertilised egg. Histopathologists subsequently applied this stem cell concept to normal and leukaemic haematopoiesis, putting forward the concept of a common progenitor of red and white blood cells <sup>2</sup> as well as a common precursor of myeloid and lymphoid leukaemic cells <sup>3</sup>. From the very beginning, the stem cell concept has thus been framed into a tree-like model, where multipotent stem cells give rise to their progeny through an ordered series of branching steps.

The first in vivo assay for stem cell function was based on the rescue of lethal irradiation through bone marrow transplantation <sup>4</sup>, followed by the first estimation of stem cell numbers by counting haematopoietic colonies in the spleens of transplanted mice (spleen colony forming unit assay, CFU-S). This not only provided an estimate of CFU-S frequency at 1 in 10,000 bone marrow cells <sup>5</sup>, but also delivered the first definitive proof for in vivo multipotent progenitor cell function based on

tracking cytogenetic abnormalities within individual CFU-S colonies<sup>6</sup>. Fluorescence activated cell sorting (FACS) subsequently facilitated the purification of transplantable hematopoietic stem cells (HSCs), with a landmark 1988 publication<sup>7</sup> demonstrating the utility of positive and negative selection. HSCs have historically been defined on the basis of two essential properties: self-renewal and multipotency. Operationally this is tested via transplantation experiments. In contrast, progenitors are defined by the absence of extended self-renewal and a restricted lineage differentiation capacity (most often bi- or unilineage), so that they are usually lost within the first 2-3 weeks after transplantation<sup>8</sup>.

Characterisation of progenitor populations downstream of the HSC resulted around the year 2000 in a model of the haematopoietic differentiation tree still shown in many textbooks today (**Fig. 1A**). In this model, the first branch point segregates lymphoid potential from all other lineages (myeloid, erythroid and megakaryocytic), followed by a number of further branching steps on either side of the tree progressing from multi- to bi- and finally unipotent progenitor cells. The subsequent introduction of additional surface markers suggested several modifications of this classical tree, including lymphoid and myeloid fates remaining associated until further down the tree<sup>8-10</sup>, early megakaryocyte branching<sup>11,12</sup> as well as subdivision of the multipotent progenitor compartment into distinct subpopulations<sup>13,14</sup> (**Fig. 1B**). Moreover, the picture is further complicated because the HSC pool itself is functionally and molecularly heterogeneous<sup>11,12,15-20</sup>. These studies are most advanced in the murine system, where we now have what at first glance appears to be a bewildering number of different structures for the haematopoietic tree. While it is likely that all these structures capture true aspects of HSC differentiation, collectively they would be difficult to squeeze into a single, rigid branching tree. New ways of not only thinking about, but also graphically representing the process of HSC differentiation are thus required. Below we will illustrate how new technologies are challenging the classical view of the hematopoietic hierarchy as a highly compartmentalised and stable structure. The emerging picture is one of a collection of heterogeneous populations organised hierarchically, with gradual progression from one to the next, and which remains highly flexible to meet the changing needs of blood demand.

## **Stem cells and progenitors boundaries**

With self-renewal and multipotency at the heart of what defines an HSC, much research has been invested into understanding the underlying cellular and molecular processes.

## **Defining the HSC state**

At the cellular level, switching off self-renewal coincides with turning on lineage programs. It thus seemed plausible that this would also be true at the molecular level, and the concept of multilineage priming was proposed early on as a possible underlying molecular mechanism by which HSCs maintain multipotentiality<sup>21</sup> (**Box1**). However the advent of genomic technologies<sup>14,22–25</sup> coupled with mouse genetics studies, has demonstrated that the HSC transcriptional programme is defined by a collection of unique metabolic and cellular properties, which are not intuitively linked directly with multipotency. Approximately 70% of all expression changes between HSCs and early progenitors occur independently of lineage choice<sup>24</sup>, with a similar dichotomy also at the levels of methylation<sup>26–29</sup> and chromatin accessibility<sup>30</sup>. Correspondingly, HSCs reside in a quiescent<sup>19,20,31,32</sup>, autophagy-dependent<sup>33,34</sup> and glycolytic<sup>35,36</sup> state marked by low mitochondrial activity<sup>37,38</sup> and tightly controlled levels of protein synthesis, below those of most other haematopoietic cell types<sup>39</sup>. Stem-cell specific stress response and quality control mechanisms allow preservation of the integrity of the HSC compartment after exposure to DNA<sup>40,41</sup> and protein damage<sup>42,43</sup> or metabolic stress<sup>33,34</sup>. In contrast, progenitors are highly proliferative and metabolically active cells dependent on oxidative metabolism and mitochondrial function.

Importantly, so-called HSC specific characteristics are not absolute: HSCs occasionally divide during homeostasis and get activated in response to stress, and therefore transiently pass through a proliferative state. It is also worth noting that early lymphoid progenitors (mouse LMPP<sup>9</sup> or human MLP<sup>8</sup>) share common transcription (TF) networks with HSCs<sup>24</sup>, which in the former push towards B cell differentiation<sup>24</sup> while in the latter inhibit self-renewal<sup>44,45</sup>. While the induction of lineage-specific transcriptional programs may occur largely independently of the loss of stem cell characteristics, regulators such as Runx1 can be involved in both<sup>46</sup> suggesting that much remains to be learned about how lineage decisions are coordinated with changes of cellular state.

### **HSC self-renewal and cell cycle interplay**

Whether the variability in HSC outputs is an intrinsic system property, a reflection of stochastic behaviour, environmental influences, technically related variability or a combination of all of these, has been and still is a subject of debate. Nonetheless, in the past 10-15 years, this heterogeneity in behaviour has been significantly formalised, and it is now accepted that HSCs are heterogeneous in terms of durability of engraftment upon transplantation, cell cycle properties and differentiation (**Table 1**).

HSCs first of all differ in the degree to which they self-renew, equating to the number of symmetric divisions that an HSC can make over its lifetime. Operationally, the field now widely accepts that, both in mouse and human, HSC that repopulate in transplantation assays for more than 16 weeks in a primary transplantation and at least in a second round of transplantation are considered Long-

Term (LT-) HSCs<sup>17,47–50</sup>. If cells can produce all differentiated cell types and engraft transiently in primary (and in some cases secondary) transplants, they are referred to as Intermediate (IT-) HSCs<sup>16</sup>, Short-Term (ST-) HSCs or MultiPotent Progenitors (MPPs)<sup>13,14,47</sup> depending on the length and robustness of the graft produced.

Heterogeneity in self-renewal capacity appears to be directly correlated to the time HSCs spend in quiescence. Label retaining studies have demonstrated that the most dormant HSCs (which retain the label over months at steady-state) display the most robust and longest repopulation capacity<sup>19,20,51–53</sup>. Two cell cycle parameters are inversely correlated with repopulation capacity: the frequency of division (length of interval between divisions), but also the time a single HSC takes to exit quiescence in vitro<sup>16,54</sup>. Of note, the level of pre-existent CDK6 mRNA and protein in quiescent HSCs directly determines the kinetics of quiescence exit<sup>54</sup>, and may thus serve as a marker of the quiescent state<sup>32,54</sup> (less CDK6 corresponding to higher dormancy). Dormancy is also associated with high levels of vitamin A metabolism via retinoic acid signalling<sup>32</sup>, high levels of p57<sup>32,55</sup>, low protein synthesis<sup>32</sup>, low Myc activity<sup>32,56</sup>, and may exist as a continuum of quiescent states between the most dormant HSCs and their activated counterparts<sup>32</sup>. While dormant HSC forced into activation by stress signals can return to dormancy<sup>19,51</sup>, Bernitz et al. estimated that 4 divisions in adulthood are sufficient for irreversible loss of self-renewal<sup>53</sup>.

A number of label-retaining assays have been developed to allow isolation of HSCs based on their division history<sup>19,20,32,51–53,57</sup>. One major limitation of all label-retaining studies to date is that the rate of symmetric divisions is inferred or indirectly measured at the bulk level. However, direct experimental measurement of asymmetric versus symmetric label-diluting divisions will be required to understand the dynamics at play within the HSC compartment. Novel integrative tools, most likely at the single cell level, will have to be developed to address this challenge. Nonetheless, it is already apparent that distinct cell cycle properties within the HSC pool are intimately linked to HSC function. Coupled with a wide range in division frequencies (depending on the HSC subset, from once a month to twice a year in mouse<sup>19,51,53,58</sup>), this means that there will be substantial variation in the contribution of distinct HSC subsets to blood formation.

### **Heterogeneity in HSC lineage output**

The capacity to give rise to all differentiated blood cell types is a fundamental aspect of what constitutes an HSC. It is however now accepted that there are distinct differentiation behaviours within the HSC and MPP<sup>13,14</sup> compartments (**Table 1, Fig. 1B**). Using limiting dilution analysis and single cell transplantation, the Müller-Sieburg and Eaves groups described HSCs that differ in their relative myeloid and lymphoid output<sup>15,59</sup>. More recently the Jacobsen and Nakauchi groups

identified HSCs that predominantly differentiate towards megakaryocytes and platelets (platelet-biased)<sup>11,12</sup>. There are however limitations to single cell transplantation, in particular that very low contributions to certain lineages may be missed. Moreover, a cell with unilineage readout may have the potential to give rise to other lineages in a durable fashion in other conditions, and both platelet-biased HSC and long-lived platelet progenitors<sup>11,60,61</sup> may coexist and be difficult to distinguish.

Importantly, HSC heterogeneity is not simply stochastic as it can be propagated through serial transplantation<sup>15,18,62,63</sup>, indicating intrinsic programming, the molecular basis for which however remains unclear. As discussed below, these findings have important conceptual implications, because they question at what cellular stage lineage choices occur. Recent evidence suggests that the overall picture may even be more complex, with distinct metabolic needs<sup>64</sup> and clonal expansion capacity of HSCs. There are examples where HSCs with high clonal expansion capacity generate subsets with lower output<sup>65</sup>, but also cases in which HSCs with very modest clonal expansion in the first transplantation, generate the most robust grafts upon serial transplantation<sup>66,67</sup>.

## Rethinking blood lineages relationships

A number of recent studies at the single cell level have questioned the routes by which lineage differentiation occurs.

### Single cell assays to study potential

Cell fate decisions (**Box 1**) are executed at the level of individual single cells. To understand their regulation, it is therefore imperative that both the biological assays testing their cellular function as well as the biochemical assays examining their molecular profiles are performed at single cell resolution. While most advanced in the mouse, in vivo transplantation assays have been and remain fundamental for our understanding of HSC biology, as the only assay that can test for HSC self-renewal. Because of the suboptimal support of human cells from the mouse microenvironment, xenotransplants cannot robustly read-out all possible differentiation routes, particularly not at single cell level. The last 10 years have therefore seen a collective effort in defining the lineage potential of single human progenitor cells by using highly defined in vitro models that can support the differentiation of most mature blood cell types. Work from the Dick and Vyas groups, together with studies in mice from the Jacobsen group described that the first restriction in lineage potential does not segregate lymphoid and myeloid potential as postulated by the CMP-CLP model (**Fig. 1A**), but that these potentials remain coupled in the LMPP<sup>9,10</sup> and MLP<sup>8</sup> compartments (**Fig. 1B**). Many other subpopulations, most with either bi- or unilineage capacity, have since been found both in the lympho-myeloid branch<sup>68</sup> and the myelo-erythroid-megakaryocytic branch<sup>69–73</sup>. Altogether it seems that few single cells read-out as multipotential within the progenitor compartment. There are

however some caveats with such interpretations, because strong instructive signals provided by the in vitro cultures, or potentially high stress levels that HSC are exposed to during single cell transplants may promote unilineage output. Moreover, a given cell may be bipotential based on its molecular state, but if it makes a lineage choice before dividing, it will read out as unipotent in functional assays. Nonetheless the evidence to date suggests that lineage choice occurs earlier than previously thought, and as recently shown for dendritic cells <sup>74</sup>, likely already within the phenotypic HSC populations.

### Single-cell transcriptional landscapes

Single cell expression analysis of RNA was first reported over 25 years ago<sup>75</sup>, but remained low throughput both in number of genes and cells until microfluidic approaches were introduced. These quickly prompted studies reporting the expression of dozens of genes in hundreds of single HSCs and progenitor cells (HSPCs)<sup>76</sup>, and provided new insights into core regulatory circuits<sup>77</sup>, novel progenitor populations<sup>70,71</sup>, cellular hierarchies in normal and transformed haematopoiesis<sup>78</sup>, dissociation between self-renewal potential and activation of lineage programs<sup>79</sup>, and the molecular overlap between HSC populations purified with four different cell sorting strategies<sup>80</sup>. However, it is not practical to assay more than 200 genes per single cell with PCR based methods, and these genes need to be predefined thus limiting the scope for novel discoveries. A real breakthrough was therefore provided by technical innovations, which now make it possible to perform transcriptome-wide RNA-Seq in thousands of single cells.

Following a landmark paper reporting the transcriptomes for more than 2600 murine single myeloid erythroid progenitor cells<sup>81</sup>, a subsequent report of 1600 transcriptomes ranging from true long-term HSCs to progenitors of all major lineages focused on generic stem cell functions such as metabolic and cell cycle status<sup>82</sup>. A number of algorithms have been developed<sup>83-87</sup> based on the idea that single cell transcriptomes represent snapshots of single cells as they traverse differentiation landscapes (**Fig. 1C**). A recent study on human bone marrow haematopoiesis comprehensively sampled the HSPC compartment<sup>88</sup>. Computational predictions suggestive of early lineage restriction were underpinned by in vitro single cell culture assays, which lead the authors to propose a model whereby acquisition of lineage-specific fates is a continuous process, and unilineage-restricted cells emerge directly from a continuum of low-primed undifferentiated haematopoietic stem and progenitor cells, without any major transition through multi- and bipotent stages. This is supported by other studies<sup>69,81,85</sup>, which highlighted the abundance of unipotent progenitors within compartments that, at the population level, are multipotent.

There are however caveats with this new model and its heavy reliance on scRNA-Seq. A major conundrum here is that surface marker combinations can readily split the HSPC compartment into

functionally distinct subpopulations, including within the space proposed to be a continuum of low-primed cells when analysed by scRNA-Seq. One possible explanation is that there is a decoupling between steady state mRNA and protein expression levels. The counter argument here is that multi-omics analysis of highly purified bulk HSPC populations has shown good concordance between mRNA and protein for the majority of genes<sup>14</sup>. It is possible also that functional heterogeneity of HSCs is primarily determined at the epigenetic level. Future measurements of chromatin accessibility and histone marks ideally at single cell resolution may reveal such mechanisms. A third possible explanation is that even though purifying cells based on protein markers followed by functional assays suggests clean splits into distinct cell types with different biological functions, the changes in biological functionality are in reality much more gradual, where there is no binary biological difference between for example LT-HSCs and MPPs, but instead any individual cell sits somewhere along a continuous spectrum. A fourth possible explanation is that current scRNA-Seq methods are not effective at distinguishing between closely related cell types, because many of the shared biological processes (e.g. cell cycle, metabolism, motility) generate substantial heterogeneity, which may exceed the number of differentially expressed genes between closely related stages of haematopoietic maturation. The degree to which early haematopoiesis is characterised by a continuum versus distinct populations therefore remains a question requiring further investigation.

## **New representations of haematopoiesis**

An immediate challenge for the field is how all the recent findings can be reconciled into new graphical models describing the hierarchical organisation of haematopoiesis. It seems clear that a tree where a circle depicts each successive restriction in potential and each circle is connected to a few others by arrows is an over-simplification. First, the circle is intuitively viewed as a homogeneous set of cells with specific characteristics, a vision incompatible with the large degree of heterogeneity observed experimentally. Second, these trees indicate a restricted set of possible transitions between circles, which likely underestimates the possible differentiation journeys in vivo. Because cell surface markers can highly enrich for particular behaviours (differentiation, self-renewal or proliferative output), a model in which all lineages branch out directly from the HSC compartment also seems somewhat unrealistic (**Fig. 1C**). We thus propose here an alternative visualisation (**Fig. 2A**), in which trajectories of differentiation are mapped over the areas that have long been represented as circles, highlighting both the diversity in possible routes and the prevalence of early lineage choice. In addition, it is important to remember that one HSC will produce a very large number of progeny, which increases exponentially with each division, an element so far ignored in graphical representations of hematopoiesis (including **Fig.2A**). Divisional histories are difficult to measure, and are likely to be heterogeneous, but should nevertheless be incorporated in future

experimental and computational analyses, which could result in new graphical representations of the blood system (Fig.2B).

## **Making blood at steady state and under stress**

In addition to defining the routes of lineage differentiation, another important question is to understand the quantitative contributions of HSCs and progenitors to daily and emergency haematopoiesis.

### **Studying unperturbed haematopoiesis**

While the haematopoietic differentiation tree is widely used as a paradigm for how a hierarchically-organized tissue is maintained, it is important to remember that this tree was largely derived from experiments that measure cell potential in colony or transplantation assays, rather than cell fate during steady state differentiation. However, if a single cell gives rise to two lineages in a colony assay, this does not prove that the same cell, when left alone in an unperturbed bone marrow environment, would have done the same. To understand the dynamics of blood formation, cells can be individually tagged (by retro- or lentiviral insertions, barcodes etc), and transplanted into recipient mice to measure the contribution of each clone over time. Progressively more sensitive methods have been used in mouse, primates and humans<sup>89–93</sup>, collectively supporting the lineage biases and/or restrictions observed in single cell transplants. Importantly, only a limited number of HSC produce the vast majority of the differentiated cells in a transplantation setting, consistent with studies of the divisional history of HSC<sup>19,20,51–53,57</sup>, which demonstrate that only the very rare most dormant HSC can provide life-long reconstitution after transplant.

Substantial excitement was raised by new technologies to assess the lineage output of individual stem and progenitor cells in unperturbed haematopoiesis<sup>94</sup>. Doxycycline induced mobilization of a sleeping beauty transposon in stem/progenitor cells was employed to generate unique integration events, which serve as barcodes then tracked by sequencing. Consequently, comparing barcodes in mature lineages following a pulse-chase label allows reconstruction of single cell behaviours in native, unperturbed haematopoiesis. In contrast to transplantation approaches, analysis of unperturbed haematopoiesis suggested that (i) MPPs contribute predominantly to the myeloid lineage during steady state, and (ii) cells functioning as HSCs in transplantation do not play a significant role in steady state haematopoiesis, which instead seems to be driven almost entirely by cells within the MPP compartment.

An alternative genetic fate mapping system based on Cre-loxP induced recombination of a transgenic barcode cassette recently achieved temporally-controlled barcode induction in single cells, and demonstrated that when HSCs are labelled at the fetal liver stage, their descendants in the adult will mostly contribute to multiple lineages<sup>95</sup>. However, megakaryocytic fate was not analysed, and when the analysis was repeated in adult bone marrow, few barcodes were detected in HSCs as well as mature progeny. Given that each fetal liver HSC divides and therefore give rises to multiple HSCs in the adult, conclusions about the lineage contribution of individual adult HSCs therefore remained preliminary. Another study from the Camargo group<sup>96</sup> addressed this issue more comprehensively by carrying out a 30-week pulse-chase experiment in adult mice with the sleeping beauty barcode system. 133 barcodes were detected in HSCs and at least one of four mature lineages (megakaryocyte, erythroid, granulocyte, B-cell). Interestingly, more than half of these 133 HSC barcodes were present only in megakaryocytes, and only a minority of the remaining barcodes were present in more than one mature lineage. Coupled with analysis at shorter pulse-chase intervals and comprehensive single cell RNA-Seq analysis, this study therefore concluded that during homeostatic unperturbed haematopoiesis, (i) megakaryocytes can arise independently from other lineages, and (ii) the phenotypic LT-HSC population as defined by transplantation assays actively contributes to megakaryocyte output.

In the HSC compartment, a transposon tag may often be present in just one or two cells, because HSC clones will rarely amplify during unperturbed haematopoiesis, thus making barcode detection less reliable. It is therefore noteworthy that both the Rodewald and Reizis groups<sup>97,98</sup> found that the HSC compartment contributed more to multilineage blood production than what was estimated by the transposon approach. Busch et al. also estimated the kinetics with which cells transit through their differentiation trajectories. Interestingly, flux into the lymphoid branch is 180 fold less than in the myeloid branch. Flux into the erythroid lineage was not assessed, but is likely to be even higher than in the myeloid (**Fig. 2b**). Flux analysis also found substantial self-renewal capacity in the ST-HSC/MPP compartment, consistent with a recent report of long-term normal haematopoiesis in mice where the HSPC compartment was ablated by 90%<sup>99</sup>.

Future approaches are likely to employ barcodes that are expressed under a strong promoter, and therefore can be detected reliably by scRNA-Seq. This would afford true single cell resolution for the analysis of clonal relationships and single cell transcriptomes, offering the exciting possibility of defining the native hierarchy agnostic of sorting strategies that were developed using transplantation. Another pertinent question is to what extent laboratory mice kept under sterile, pathogen-free conditions are a suitable model for human haematopoiesis, which is constantly challenged by exposure to infectious agents, and has to function over a much longer lifespan. Long-term follow-up of autologous transplant patients has already revealed previously unknown functional aspects of human haematopoiesis, such as the number, stability and dynamics of

individual HSCs over many years<sup>100</sup>. Background somatic mutations represent unique barcodes that can be exploited to reconstruct clonal lineage relationships<sup>101,102</sup> and may thus represent another approach to investigate the dynamics of single human HSPCs over extended periods of time.

### **Hematopoiesis is flexible in space and time**

Blood production needs to have the flexibility to adapt to drastic changes of demand, with evidence accumulating that HSC properties and differentiation journeys can adapt. As reviewed elsewhere<sup>103</sup>, haematopoietic development in the embryo is complex, with a series of transient haematopoietic waves across several organs (**Fig. 3**). Importantly, fetal and adult HSC have fundamentally different regulation and behaviours (reviewed in<sup>104</sup>). In mice, there is a switch from a proliferative to a quiescent state between 3 and 4 weeks of age, which coincides with decrease in self-renewal<sup>105</sup>. In humans, the timing of the fetal to adult switch somewhat differs. When compared to adult bone marrow, human HSCs from neonatal cord blood have increased proliferative potential (as expected from mouse studies), but their cell cycle properties already resemble the adult configuration<sup>54</sup>. Consistently, telomere length in granulocytes, a surrogate for HSC division rate, rapidly declines during the first year of human life<sup>106</sup>. There is evidence also that terminally differentiated cells are produced differently during fetal and adult hematopoiesis, because many more single progenitor cells from human fetal liver produce 2 lineages or more than from adult bone marrow<sup>69</sup>. Interestingly, the relative proportion of HSC subsets also change over time with balanced HSC predominating in fetal liver, while lymphoid-deficient (also called myeloid-biased) HSC accumulate during ageing<sup>107</sup>. The effects of ageing on HSC and more generally blood production are numerous and have been reviewed elsewhere<sup>108</sup>. Changes in both the composition of the HSC pool<sup>107,109,110</sup> as well as the molecular circuitry of individual HSCs<sup>34,111–113</sup> can be due to either extrinsic or intrinsic properties, including alterations in the microenvironment, the proliferative history and accumulation of mutations.

The HSC niche is a highly complex ecosystem that sustains HSC function, in particular promoting survival and long-term maintenance of the HSC pool<sup>114</sup>. If and how niche interactions shape the activity of distinct HSC subsets and the differentiation journeys of HSCs remains unclear. Single cell transplants and clonal tracking have shown that clones display stereotypical behaviour over serial rounds of transplantation, arguing that their characteristic outputs are not extensively niche-dependent<sup>15,59,62,63</sup>. However, it is possible that distinct HSC subsets may have different niche preferences. Furthermore, even though the vast majority of HSC are located in the bone marrow in adults, a small percentage of HSC are released in the blood with circadian-clock controlled patterns<sup>115</sup>, and HSCs can be found also in the spleen<sup>116</sup> and lungs<sup>117</sup> (**Fig. 3**). The role of these extra-medullary niches and whether they host specific subsets of HSC or influence their differentiation or

clonal expansion capacity will have to be explored at single cell resolution. Finally, many types of stress directly affect HSC function: DNA damage<sup>40,41</sup>, inflammation<sup>118</sup>, acute or chronic infection<sup>119,120</sup>, psychosocial stress<sup>121</sup>, metabolic stress<sup>33</sup> and obesity<sup>122</sup>. For most of these processes, insights have been gained on the molecular mechanisms driving the changes in HSC or progenitor cell function. Interestingly though, there are also examples showing that, at the cellular level, not all HSC or progenitor subsets equally respond to these stresses. For example, in emergency myelopoiesis, MPP2 and MPP3 drive enhanced production of GMPs<sup>13,123</sup>, which reorganise themselves spatially and activate a self-renewal network<sup>123</sup>. We are thus only beginning to understand how stress responses can reshape the relative abundance and possibly differentiation trajectories of different HSPC subsets, and less still is known about the cellular and molecular control/feed-back mechanisms that maintain and/or re-establish homeostasis.

## Implications for Human Disease

Our understanding of haematopoiesis is currently undergoing a number of shifts. These include: (i) demarcations between stem and progenitor cells that previously were considered rather rigid are becoming increasingly blurred, (ii) cell fate choices upstream of the classically defined bi-/oligopotent progenitor cells may be more prevalent than previously thought, (iii) the loss of key stem cell characteristics may be largely decoupled from the initiation of specific lineage differentiation programmes, and (iv) measuring cellular fates in vivo without the need for highly disruptive transplantation procedures has highlighted a previously underappreciated importance of ST-HSC/MPPs in unperturbed haematopoiesis. These and other revisions of our understanding of haematopoiesis as a stem cell developmental system have major implications for the diagnosis, prognosis and treatment of haematological diseases.

Haematology as a clinical discipline has a long track record of being an early adopter of the latest technological developments, which recently included the first successful gene therapy trials<sup>124,125</sup> as well as some of the first comprehensive cancer genome studies<sup>126</sup>. With respect to haematopoietic malignancies, much current research focuses on identifying the cell of origin, which acquired the first somatic mutation within the multistep progression towards a full-blown malignancy. It is widely accepted now that stem and progenitor cells play a major role in the development of myeloid malignancies (CML, AML) and myeloproliferative neoplasms. More recent evidence also implicates HSCs and lymphoid progenitors in the early stages of hairy cell leukemia<sup>127</sup> and lymphoma<sup>128</sup>. It is beyond the scope of this review to list the effects of each of the driver mutations on HSC and progenitor cell function, but it is worth noting that each one of them will reshape the balance of

differentiation trajectories and generate complex clonal dynamic patterns. Since cellular context influences the potential impact of leukaemogenic mutations, the newly recognized fluidity of cellular states within the HSPC compartment implies greater disease heterogeneity between patients, because even when two patients carry identical founder mutations, the likelihood that they arose in identical cellular states is small. Moreover, the malignant transformation is likely to open up new molecular states/trajectories. In AML for example, leukemic stem cells are defined by a chimeric transcriptional state<sup>10,129</sup>, and single cell proteomic approaches have demonstrated the existence of distinct differentiation trajectories for malignant cells<sup>130</sup>.

Given the increasing recognition of discrepancies between the clonal behaviour of native unperturbed HSPCs versus transplantation, xenotransplantation of human leukaemic cells into immune-compromised mice will share similar limitations, where exposing leukaemic cells to a transplantation assay may induce cellular behaviour that would never occur in a human patient. Exciting prospects may be offered here by new models that may permit transplantation without irradiation<sup>131</sup> and the use of ossicles templated with human bone marrow stromal cells<sup>132,133</sup>. It nevertheless seems imperative to invigorate research efforts that directly track disease in human patients. This will require careful design of patient cohorts and new screening technologies, including multi-omics single cell technologies to define the cellular state as well as the mutation burden of individual cells, as demonstrated recently for BCR-ABL<sup>134</sup>.

Bone marrow transplantation is likely to remain an important curative therapy for many leukaemia patients, and with progress in the cell and gene therapy field, may find much wider applicability. Since suitable donor material for bone marrow transplantation remains rate limiting, one promising avenue here is to produce HSCs from other cell types by borrowing regulatory processes known to be important during developmental haematopoiesis, as illustrated by the recent generation of stem cells with long-term engrafting capability from human pluripotent and mouse adult endothelial cells<sup>135,136</sup>. A better understanding of the HSC state and cell fate decision making will provide new avenues to develop protocols for in vitro amplification of HSCs<sup>137–139</sup>, and also facilitate optimization of protocols for robust genome engineering of HSCs with vast potential for treating common diseases ranging from inherited red blood cell to autoimmune disorders. Expansion of clinical applications will greatly benefit from a better understanding of the self-renewal and differentiation potential of individual HSPCs, coupled with robust prediction algorithms from molecular profiling data to evaluate the efficacy of cell therapy products. Haematopoiesis is therefore well positioned to lead the way in the gene and cell therapy arena, and we may not be too far away from a future

where haematopoiesis will be firmly established not just as a stem cell, but also as a therapeutic paradigm.

#### ACKNOWLEDGMENTS

We thank Dr David Kent for critical reading of the manuscript. E.L. is supported by a Sir Henry Dale fellowship from the Wellcome Trust (WT)/Royal Society. Research in the Laurenti and Gottgens laboratories is supported by the WT, CRUK, Bloodwise, MRC, BBSRC, NIH-NIDDK, and core support grants by the WT and MRC to the WT-MRC Cambridge Stem Cell Institute.

#### AUTHORS' CONTRIBUTIONS

E.L. and B.G. contributed equally to the writing and editing of the manuscript as well as to figure preparation.

## TABLES

**Table 1: summary of phenotypic or functionally defined HSC subsets reported to date.**

Listed are subtypes of HSCs defined based on combinations of cell surface markers and/or function. A global interpretation of the literature on HSC biology is complicated by the fact that each study usually uses only one of the classification schemes below, so the extent of overlap between HSC subsets remains to be clarified. N.A.: not assessed.

Species	Name	Cell surface phenotype	Self-renewal	Cell cycle properties	Differentiation	Refs
Mouse	LT-HSC	$Lin^- Sca1^+ cKit^+$ $CD34^- CD150^+$ $CD135^- CD48^\pm$ $EPCR^\pm Rho^{lo}$	High			17,47,48,140
	IT-HSC	$Lin^- Sca1^+ cKit^+$ $CD34^{lo} CD135^-$ $Rho^{lo} CD49b^{hi}$	Intermediate	Short G <sub>0</sub> exit		16
	ST-HSC/MPP1	$Lin^- Sca1^+ cKit^+$ $CD135^- CD150^-$ $CD48^-$	Low			
	$\alpha$	N.A.	High	N.A.	Ly-deficient	15,107
	$\beta$	N.A.	High	N.A.	Balanced	
	$\gamma$	N.A.	Intermediate	N.A.	My-deficient	
	$\delta$	N.A.	Low	N.A.	My-deficient	
	MPP2	$Lin^- Sca1^+ cKit^{+o}$ $CD135^- CD150^+$ $CD48^+$	Low	similar	Ly-deficient	13,14
	MPP3	$Lin^- Sca1^+ cKit^{+o}$ $CD135^- CD150^-$ $CD48^+$	Low		Balanced	
	MPP4	$Lin^- Sca1^+ cKit^{+o}$ $CD135^+ CD150^-$ $CD48^+$	Low		Ly-biased	
	d-HSC	N.A.	Higher	dormant		19,20,51–53
	a-HSC	N.A.	Lower	activated		
Human	LT-HSC	$Lin^- CD34^+$ $CD38^- CD45RA^-$ $CD49f^+ CD90^\pm$ $Rho^{lo}$	High	Long G <sub>0</sub> exit		50,54
	ST-HSC/MPP	$Lin^- CD34^+$ $CD38^- CD45RA^-$ $CD49f^+ CD90^+$	Low	Short G <sub>0</sub> exit		
	CD34 <sup>-</sup> LT-HSC	$Lin^- CD34^-$ $CD38^- CD93^{hi}$	High	Highly quiescent		66

## FIGURES

### Fig.1: Timeline of hierarchical models of hematopoiesis.

**A.** Visualisation based on state-of-the-art around the year 2000: HSCs are represented as a homogeneous population downstream of which the first lineage bifurcation separates the myeloid and lymphoid branches via the CMP and CLP populations; **B.** During the years 2005 to 2015 this visualisation incorporates new findings: the HSC pool is now accepted to be more heterogeneous both in terms of self-renewal (vertical axis) and differentiation properties (horizontal axis), the myeloid and lymphoid branches remain associated further down in the hierarchy via the LMPP population, the GMP compartment is shown to be fairly heterogeneous<sup>141</sup>. **C.** From 2016 onwards, single cell transcriptomics snapshots indicate a continuum of differentiation. Each red dot represents a single cell and its localisation along a differentiation trajectory.

### Fig.2: Trajectory based visualizations of the hematopoietic hierarchy.

**A.** 2D visualisation of early hematopoiesis. Continuous lines: trajectories of differentiation for different types of single cells present in the phenotypic HSC compartment (grey shaded area). Along these trajectories, cells and their progeny pass through progenitor compartments commonly defined by specific combinations of cell surface markers (shaded areas). Horizontal lines represent snapshots of the lineage potential of the cells present in each phenotypic compartment (single colour circles: unilineage cells, 2 colours circles: bi-lineage cells, 3 colours circles: tri-lineage cells, black circles: multipotent cells). In most progenitor compartments the number of unilineage cells outnumbers that of bi- or tri-lineage ones. The figure illustrates differentiation trajectories reported in the literature to date, but their proportions may not reflect the in vivo situation. **B.** 3D visualisation of the progeny of one single HSC. Red, blue and green respectively represent the erythroid, myeloid and lymphoid lineage. Cell history, division and progenitor expansion should all be considered when modelling the differentiation journey of one HSC and all its progeny. In an adult human, there are an estimated 3000-10000 HSCs, which most likely divide only from once every 3 months to once every 3 years<sup>58</sup>. Humans produce an estimated  $1.4 \times 10^{14}$  mature blood cells/year<sup>142</sup>. The amplification from a few thousand HSCs therefore is staggering and must include a strong contribution from a transient-amplifying compartment. Also, because there are many more terminally differentiated erythroid cells than myeloid cells, and even less lymphoid cells, all with different turn-over rates, the flux into each compartment must be highly regulated.

**Fig.3: The composition of the HSPC compartment changes in space and time.**

HSPCs are found in many organs in the body across a lifetime. Cells of different colours represent distinct HSPC subsets. To date it is unclear whether all HSPC subsets and differentiation trajectories are present in the same proportions in each of the organs. Current evidence suggests that age-related changes result from a combination of shifts in the composition of the HSPC pool, as well as phenotypic changes in particular cell types driven by intrinsic genetic and epigenetic changes as well as systemic alterations of the microenvironment. AGM: Aorta Gonad Mesonephros.

**BOXES**

**BOX1: Mechanistic underpinnings of cell fate choice**

Cell fate decisions entail a choice between alternative gene expression programs, executed by transcriptional and epigenetic regulators. Transcription factors (TFs) bind specific sequence motifs within promoter, enhancer and silencer regions. Cell type specific expression is achieved through combinatorial TF interactions, which form key building blocks of wider regulatory networks. TF complexes recruit epigenetic regulators to modulate the activation status of a gene locus, which can be transmitted to subsequent cell generations as so-called “epigenetic memory”. Importantly, a progenitor cell can become primed by opening up regulatory elements associated with genes that drive differentiation down a specific mature lineage<sup>143</sup>.

Multipotent cells are believed to exhibit multilineage priming, which entails simultaneous, low-level activation of expression programs for alternate lineages. Lineage choice then constitutes one program “winning out” while the alternative program is extinguished. Cross-antagonism between pairs of lineage-determining TFs represents an attractive mechanistic model, which initially focussed on the erythroid regulator Gata1 and the myeloid regulator Pu.1. More recent single cell time-lapse imaging however questioned whether an erythroid / myeloid fate choice is indeed driven primarily by Gata1/Pu.1 cross-antagonism<sup>144</sup>. Evidence for lineage priming and its resolution by TF cross-antagonism has been reported at single cell resolution for other TF pairs, such as the neutrophil/macrophage fate choice controlled by Gfi1 / Irf8<sup>87</sup>.

Both instructive and stochastic models have been proposed as mechanisms triggering the upregulation of one lineage program over another. Stochastic here generally refers to random, unequal distribution of molecules following cell division. Instructive models posit that low-level expression of a cytokine receptor is sufficient for a cell to be responsive to external signals, as shown

for a number of myeloid cytokines<sup>145</sup>. Autoregulation and feed forward loops also play important roles in fate choice decisions. For example, Gata1 positive autoregulation stabilizes erythroid fate<sup>146</sup>, Pu.1 positive autoregulation stabilizes myeloid identity<sup>147</sup>, and the highly connected triad of Gata2, Tal1/Scl and Fli1 is thought to stabilize the stem/progenitor state<sup>148,149</sup>. In feed forward loops, an upstream regulator induces its target directly as well as through an intermediate regulator<sup>150</sup>. Feed-forward motifs can filter out transient signals, and when coupled with autoregulation, generate forward momentum.

511

512 **REFERENCES**

- 513 1. Haeckel, E. *Natürliche Schöpfungsgeschichte*. (Georg Reimer, 1868).
- 514 2. Pappenheim, A. Ueber Entwicklung und Ausbildung der Erythroblasten. *Virchows Arch*  
515 *Pathol Anat* **145**, 587–643 (1896).
- 516 3. Pappenheim, A. Zwei Fälle akuter grosslymphozytärer Leukämie. *Fol Haematol* **4**, 301–  
517 308 (1907).
- 518 4. Jacobson, L. O., Simmons, E. L., Marks, E. K. & Eldredge, J. H. Recovery from Radiation  
519 Injury. *Science* **113**, 510–511 (1951).
- 520 5. Till, J. E. & McCulloch, E. A. A direct measurement of the radiation sensitivity of normal  
521 mouse bone marrow cells. *Radiat. Res.* **14**, 213–222 (1961).
- 522 6. Becker, A. J., McCULLOCH, E. A. & Till, J. E. Cytological demonstration of the clonal  
523 nature of spleen colonies derived from transplanted mouse marrow cells. *Nature* **197**,  
524 452–454 (1963).
- 525 7. Spangrude, G. J., Heimfeld, S. & Weissman, I. L. Purification and characterization of  
526 mouse hematopoietic stem cells. *Science* **241**, 58–62 (1988).
- 527 8. Doulatov, S. *et al.* Revised map of the human progenitor hierarchy shows the origin of  
528 macrophages and dendritic cells in early lymphoid development. *Nat. Immunol.* **11**,  
529 585–593 (2010).
- 530 9. Adolfsson, J. *et al.* Identification of Flt3+ lympho-myeloid stem cells lacking erythro-  
531 megakaryocytic potential a revised road map for adult blood lineage commitment. *Cell*  
532 **121**, 295–306 (2005).
- 533 10. Goardon, N. *et al.* Coexistence of LMPP-like and GMP-like leukemia stem cells in acute  
534 myeloid leukemia. *Cancer Cell* **19**, 138–152 (2011).
- 535 11. Sanjuan-Pla, A. *et al.* Platelet-biased stem cells reside at the apex of the haematopoietic  
536 stem-cell hierarchy. *Nature* **502**, 232–236 (2013).

537 **First evidence of an HSC differentiation bias along the megakaryocyte-platelet lineage.**  
538

539 12. Yamamoto, R. *et al.* Clonal Analysis Unveils Self-Renewing Lineage-Restricted  
540 Progenitors Generated Directly from Hematopoietic Stem Cells. *Cell* **154**, 1112–1126  
541 (2013).

542 **Comprehensive single cell transplantation study demonstrating that single cells can repopulate**  
543 **long-term after transplantation without contributing to all blood lineages.**  
544

545 13. Pietras, E. M. *et al.* Functionally Distinct Subsets of Lineage-Biased Multipotent  
546 Progenitors Control Blood Production in Normal and Regenerative Conditions. *Cell Stem*  
547 *Cell* **17**, 35–46 (2015).

548 **Evidence of lineage-biases in MPP populations.**  
549

550 14. Cabezas-Wallscheid, N. *et al.* Identification of regulatory networks in HSCs and their  
551 immediate progeny via integrated proteome, transcriptome, and DNA methylome  
552 analysis. *Cell Stem Cell* **15**, 507–522 (2014).

553 15. Dykstra, B. *et al.* Long-Term Propagation of Distinct Hematopoietic Differentiation  
554 Programs In Vivo. *Cell Stem Cell* **1**, 218–229 (2007).

555 16. Benveniste, P. *et al.* Intermediate-Term Hematopoietic Stem Cells with Extended but  
556 Time-Limited Reconstitution Potential. *Cell Stem Cell* **6**, 48–58 (2010).

557 17. Kiel, M. J. *et al.* SLAM Family Receptors Distinguish Hematopoietic Stem and Progenitor  
558 Cells and Reveal Endothelial Niches for Stem Cells. *Cell* **121**, 1109–1121 (2005).

559 18. Müller-Sieburg, C. E., Cho, R. H., Thoman, M., Adkins, B. & Sieburg, H. B. Deterministic  
560 regulation of hematopoietic stem cell self-renewal and differentiation. *Blood* **100**, 1302–  
561 1309 (2002).

562 19. Wilson, A. *et al.* Hematopoietic Stem Cells Reversibly Switch from Dormancy to Self-  
563 Renewal during Homeostasis and Repair. *Cell* **135**, 1118–1129 (2008).

20. Foudi, A. *et al.* Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells. *Nat. Biotechnol.* **27**, 84–90 (2009).
21. Miyamoto, T. *et al.* Myeloid or Lymphoid Promiscuity as a Critical Step in Hematopoietic Lineage Commitment. *Dev. Cell* **3**, 137–147 (2002).
22. Chambers, S. M. *et al.* Hematopoietic fingerprints: an expression database of stem cells and their progeny. *Cell Stem Cell* **1**, 578–591 (2007).
23. Novershtern, N. *et al.* Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis. *Cell* **144**, 296–309 (2011).
24. Laurenti, E. *et al.* The transcriptional architecture of early human hematopoiesis identifies multilevel control of lymphoid commitment. *Nat. Immunol.* **14**, 756–763 (2013).
25. Chen, L. *et al.* Transcriptional diversity during lineage commitment of human blood progenitors. *Science* **345**, 1251033 (2014).
26. Bock, C. *et al.* DNA Methylation Dynamics during In Vivo Differentiation of Blood and Skin Stem Cells. *Mol. Cell* **47**, 633–647 (2012).
27. Farlik, M. *et al.* DNA Methylation Dynamics of Human Hematopoietic Stem Cell Differentiation. *Cell Stem Cell* **19**, 808–822 (2016).
28. Bocker, M. T. *et al.* Genome-wide promoter DNA methylation dynamics of human hematopoietic progenitor cells during differentiation and aging. *Blood* **117**, e182–e189 (2011).
29. Ji, H. *et al.* Comprehensive methylome map of lineage commitment from haematopoietic progenitors. *Nature* **467**, 338–342 (2010).
30. Corces, M. R. *et al.* Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. *Nat. Genet.* **48**, 1193–1203 (2016).

31. Cheshier, S. H., Morrison, S. J., Liao, X. & Weissman, I. L. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. *Proc. Natl. Acad. Sci.* **96**, 3120–3125 (1999).
32. Cabezas-Wallscheid, N. *et al.* Vitamin A-Retinoic Acid Signaling Regulates Hematopoietic Stem Cell Dormancy. *Cell* **169**, 807–823.e19 (2017).
- Comprehensive study describing the molecular circuitry that maintains dormant HSCs.**
33. Warr, M. R. *et al.* FOXO3A directs a protective autophagy program in haematopoietic stem cells. *Nature* **494**, 323–327 (2013).
34. Ho, T. T. *et al.* Autophagy maintains the metabolism and function of young and old stem cells. *Nature* **543**, 205–210 (2017).
35. Simsek, T. *et al.* The Distinct Metabolic Profile of Hematopoietic Stem Cells Reflects Their Location in a Hypoxic Niche. *Cell Stem Cell* **7**, 380–390 (2010).
36. Takubo, K. *et al.* Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. *Cell Stem Cell* **12**, 49–61 (2013).
37. Vannini, N. *et al.* Specification of haematopoietic stem cell fate via modulation of mitochondrial activity. *Nat. Commun.* **7**, 13125 (2016).
38. Ito, K. *et al.* Self-renewal of a purified Tie2<sup>+</sup> hematopoietic stem cell population relies on mitochondrial clearance. *Science* aaf5530 (2016). doi:10.1126/science.aaf5530
39. Signer, R. A. J., Magee, J. A., Salic, A. & Morrison, S. J. Haematopoietic stem cells require a highly regulated protein synthesis rate. *Nature* **509**, 49–54 (2014).
40. Mohrin, M. *et al.* Hematopoietic Stem Cell Quiescence Promotes Error-Prone DNA Repair and Mutagenesis. *Cell Stem Cell* **7**, 174–185 (2010).
41. Milyavsky, M. *et al.* A Distinctive DNA Damage Response in Human Hematopoietic Stem Cells Reveals an Apoptosis-Independent Role for p53 in Self-Renewal. *Cell Stem Cell* **7**, 186–197 (2010).

42. van Galen, P. *et al.* The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress. *Nature* **510**, 268–272 (2014).
43. Mohrin, M. *et al.* A mitochondrial UPR-mediated metabolic checkpoint regulates hematopoietic stem cell aging. *Science* **347**, 1374–1377 (2015).
44. van Galen, P. *et al.* Reduced Lymphoid Lineage Priming Promotes Human Hematopoietic Stem Cell Expansion. *Cell Stem Cell* **14**, 94–106 (2014).
45. Beer, P. A. *et al.* A Dominant-Negative Isoform of IKAROS Expands Primitive Normal Human Hematopoietic Cells. *Stem Cell Rep.* **3**, 841–857 (2014).
46. Cai, X. *et al.* Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells. *Cell Stem Cell* **17**, 165–177 (2015).
47. Oguro, H., Ding, L. & Morrison, S. J. SLAM Family Markers Resolve Functionally Distinct Subpopulations of Hematopoietic Stem Cells and Multipotent Progenitors. *Cell Stem Cell* **13**, 102–116 (2013).
48. Kent, D. G. *et al.* Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. *Blood* **113**, 6342–6350 (2009).
49. Majeti, R., Park, C. Y. & Weissman, I. L. Identification of a Hierarchy of Multipotent Hematopoietic Progenitors in Human Cord Blood. *Cell Stem Cell* **1**, 635–645 (2007).
50. Notta, F. *et al.* Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. *Science* **333**, 218–221 (2011).
51. Takizawa, H., Regoes, R. R., Boddupalli, C. S., Bonhoeffer, S. & Manz, M. G. Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation. *J. Exp. Med.* **208**, 273–284 (2011).

52. Qiu, J., Papatsenko, D., Niu, X., Schaniel, C. & Moore, K. Divisional History and Hematopoietic Stem Cell Function during Homeostasis. *Stem Cell Rep.* **2**, 473–490 (2014).
53. Bernitz, J. M., Kim, H. S., MacArthur, B., Sieburg, H. & Moore, K. Hematopoietic Stem Cells Count and Remember Self-Renewal Divisions. *Cell* **167**, 1296–1309.e10 (2016).
54. Laurenti, E. *et al.* CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells. *Cell Stem Cell* **16**, 302–313 (2015).
- Demonstration of the molecular mechanism by which distinct quiescence exit kinetics are differentially maintained in distinct HSC subsets.**
55. Zou, P. *et al.* p57Kip2 and p27Kip1 Cooperate to Maintain Hematopoietic Stem Cell Quiescence through Interactions with Hsc70. *Cell Stem Cell* **9**, 247–261 (2011).
56. Laurenti, E. *et al.* Hematopoietic Stem Cell Function and Survival Depend on c-Myc and N-Myc Activity. *Cell Stem Cell* **3**, 611–624 (2008).
57. Säwén, P. *et al.* Mitotic History Reveals Distinct Stem Cell Populations and Their Contributions to Hematopoiesis. *Cell Rep.* **14**, 2809–2818 (2016).
58. Catlin, S. N., Busque, L., Gale, R. E., Gutter, P. & Abkowitz, J. L. The replication rate of human hematopoietic stem cells in vivo. *Blood* **117**, 4460–4466 (2011).
59. Muller-Sieburg, C. E., Cho, R. H., Karlsson, L., Huang, J.-F. & Sieburg, H. B. Myeloid-biased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness. *Blood* **103**, 4111–4118 (2004).
60. Haas, S. *et al.* Inflammation-Induced Emergency Megakaryopoiesis Driven by Hematopoietic Stem Cell-like Megakaryocyte Progenitors. *Cell Stem Cell* **17**, 422–434 (2015).
61. Roch, A., Trachsel, V. & Lutolf, M. P. Brief Report: Single-Cell Analysis Reveals Cell Division-Independent Emergence of Megakaryocytes From Phenotypic Hematopoietic Stem Cells. *STEM CELLS* **33**, 3152–3157 (2015).

663 62. Yu, V. W. C. *et al.* Epigenetic Memory Underlies Cell-Autonomous Heterogeneous  
664 Behavior of Hematopoietic Stem Cells. *Cell* **167**, 1310–1322.e17 (2016).

665 63. Challen, G. A., Boles, N. C., Chambers, S. M. & Goodell, M. A. Distinct Hematopoietic  
666 Stem Cell Subtypes Are Differentially Regulated by TGF- $\beta$ 1. *Cell Stem Cell* **6**, 265–278  
667 (2010).

668 64. Luchsinger, L. L., de Almeida, M. J., Corrigan, D. J., Mumau, M. & Snoeck, H.-W.  
669 Mitofusin 2 maintains haematopoietic stem cells with extensive lymphoid potential.  
670 *Nature* **529**, 528–531 (2016).

671 65. Grinenko, T. *et al.* Clonal expansion capacity defines two consecutive developmental  
672 stages of long-term hematopoietic stem cells. *J. Exp. Med.* jem.20131115 (2014).  
673 doi:10.1084/jem.20131115

674 66. Anjos-Afonso, F. *et al.* CD34<sup>+</sup> Cells at the Apex of the Human Hematopoietic Stem Cell  
675 Hierarchy Have Distinctive Cellular and Molecular Signatures. *Cell Stem Cell* **13**, 161–174  
676 (2013).

677 67. Morita, Y., Ema, H. & Nakauchi, H. Heterogeneity and hierarchy within the most  
678 primitive hematopoietic stem cell compartment. *J. Exp. Med.* **207**, 1173–1182 (2010).

679 68. Kohn, L. A. *et al.* Lymphoid priming in human bone marrow begins before expression of  
680 CD10 with upregulation of L-selectin. *Nat. Immunol.* (2012). doi:10.1038/ni.2405

681 69. Notta, F. *et al.* Distinct routes of lineage development reshape the human blood  
682 hierarchy across ontogeny. *Science* **351**, aab2116 (2016).

683 **Study demonstrating that the structure of the hematopoietic hierarchy and the differentiation**  
684 **journeys downstream of HSCs change over a human lifetime.**

685

686 70. Psaila, B. *et al.* Single-cell profiling of human megakaryocyte-erythroid progenitors  
687 identifies distinct megakaryocyte and erythroid differentiation pathways. *Genome Biol.*  
688 **17**, 83 (2016).

689 71. Miyawaki, K. *et al.* Identification of unipotent megakaryocyte progenitors in human  
690 hematopoiesis. *Blood* blood-2016-09-741611 (2017). doi:10.1182/blood-2016-09-  
691 741611

692 72. Sanada, C. *et al.* Adult human megakaryocyte-erythroid progenitors are in the  
693 CD34+CD38mid fraction. *Blood* **128**, 923–933 (2016).

694 73. Pronk, C. J. H. *et al.* Elucidation of the Phenotypic, Functional, and Molecular  
695 Topography of a Myeloerythroid Progenitor Cell Hierarchy. *Cell Stem Cell* **1**, 428–442  
696 (2007).

697 74. Lee, J. *et al.* Lineage specification of human dendritic cells is marked by IRF8 expression  
698 in hematopoietic stem cells and multipotent progenitors. *Nat. Immunol.* **18**, 877–888  
699 (2017).

700 75. Brady, Gerard, Barbara, Mary & Iscove, Norman. Representative in Vitro cDNA  
701 Amplification From Individual Hemopoietic Cells and Colonies. *METHODS Mol. Cell. Biol.*  
702 17–25 (1990).

703 76. Warren, L., Bryder, D., Weissman, I. L. & Quake, S. R. Transcription factor profiling in  
704 individual hematopoietic progenitors by digital RT-PCR. *Proc. Natl. Acad. Sci. U. S. A.*  
705 **103**, 17807–17812 (2006).

706 77. Moignard, V. *et al.* Characterisation of transcriptional networks in blood stem and  
707 progenitor cells using high-throughput single cell gene expression analysis. *Nat. Cell Biol.*  
708 **15**, 363–372 (2013).

709 78. Guo, G. *et al.* Mapping Cellular Hierarchy by Single-Cell Analysis of the Cell Surface  
710 Repertoire. *Cell Stem Cell* **13**, 492–505 (2013).

711 79. Pina, C. *et al.* Inferring rules of lineage commitment in haematopoiesis. *Nat. Cell Biol.* **14**,  
712 287–294 (2012).

80. Wilson, N. K. *et al.* Combined Single-Cell Functional and Gene Expression Analysis Resolves Heterogeneity within Stem Cell Populations. *Cell Stem Cell* **16**, 712–724 (2015).
81. Paul, F. *et al.* Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors. *Cell* **163**, 1663–1677 (2015).
- Comprehensive single cell RNA-seq study of the myelo-erythroid progenitor compartment.**
82. Nestorowa, S. *et al.* A single cell resolution map of mouse haematopoietic stem and progenitor cell differentiation. *Blood* blood-2016-05-716480 (2016). doi:10.1182/blood-2016-05-716480
- Study providing the first description of the whole hematopoietic hierarchy by single cell RNA-seq.**
83. Trapnell, C. *et al.* The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat. Biotechnol.* **32**, 381–386 (2014).
84. Haghverdi, L., Buettner, F. & Theis, F. J. Diffusion maps for high-dimensional single-cell analysis of differentiation data. *Bioinforma. Oxf. Engl.* **31**, 2989–2998 (2015).
85. Grün, D. *et al.* De Novo Prediction of Stem Cell Identity using Single-Cell Transcriptome Data. *Cell Stem Cell* **19**, 266–277 (2016).
86. Setty, M. *et al.* Wishbone identifies bifurcating developmental trajectories from single-cell data. *Nat. Biotechnol.* **34**, 637–645 (2016).
87. Olsson, A. *et al.* Single-cell analysis of mixed-lineage states leading to a binary cell fate choice. *Nature advance online publication*, (2016).
88. Velten, L. *et al.* Human haematopoietic stem cell lineage commitment is a continuous process. *Nat. Cell Biol.* **19**, 271–281 (2017).
- Study coupling single cell RNA-seq and index sorting to delineate differentiation journeys of human HSCs.**
89. Naik, S. H. *et al.* Diverse and heritable lineage imprinting of early haematopoietic progenitors. *Nature* **496**, 229–232 (2013).

90. Lu, R., Neff, N. F., Quake, S. R. & Weissman, I. L. Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. *Nat. Biotechnol.* **29**, 928–933 (2011).
91. Cheung, A. M. S. *et al.* Analysis of the clonal growth and differentiation dynamics of primitive barcoded human cord blood cells in NSG mice. *Blood* **122**, 3129–3137 (2013).
92. Dick, J. E., Magli, M. C., Huszar, D., Phillips, R. A. & Bernstein, A. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/W<sup>v</sup> mice. *Cell* **42**, 71–79 (1985).
93. Lemischka, I. R., Raulet, D. H. & Mulligan, R. C. Developmental potential and dynamic behavior of hematopoietic stem cells. *Cell* **45**, 917–927 (1986).
94. Sun, J. *et al.* Clonal dynamics of native haematopoiesis. *Nature* **514**, 322–327 (2014).
95. Pei, W. *et al.* Polylox barcoding reveals haematopoietic stem cell fates realized in vivo. *Nature advance online publication*, (2017).
96. Rodriguez-Fraticelli, A. E. *et al.* Clonal analysis of lineage fate in unperturbed hematopoiesis. *Nature in press*,  
**Clonal tracking analysis of unperturbed hematopoiesis reveals large contribution of single phenotypic HSC to the production of megakaryocytes and platelets at homeostasis.**
97. Sawai, C. M. *et al.* Hematopoietic Stem Cells Are the Major Source of Multilineage Hematopoiesis in Adult Animals. *Immunity* **45**, 597–609 (2016).
98. Busch, K. *et al.* Fundamental properties of unperturbed haematopoiesis from stem cells in vivo. *Nature* **518**, 542–546 (2015).  
**Clonal tracking analysis coupled with mathematical modeling defined the flux of stem cells into the different lineage branches under unperturbed and transplantation conditions.**
99. Schoedel, K. B. *et al.* The bulk of the hematopoietic stem cell population is dispensable for murine steady-state and stress hematopoiesis. *Blood* blood-2016-03-706010 (2016). doi:10.1182/blood-2016-03-706010

100. Biasco, L. *et al.* In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases. *Cell Stem Cell* **19**, 107–119 (2016).
101. Behjati, S. *et al.* Genome sequencing of normal cells reveals developmental lineages and mutational processes. *Nature* **513**, 422–425 (2014).
102. Biezuner, T. *et al.* A generic, cost-effective, and scalable cell lineage analysis platform. *Genome Res.* (2016). doi:10.1101/gr.202903.115
103. Ivanovs, A. *et al.* Human haematopoietic stem cell development: from the embryo to the dish. *Development* **144**, 2323–2337 (2017).
104. Copley, M. R. & Eaves, C. J. Developmental changes in hematopoietic stem cell properties. *Exp. Mol. Med.* **45**, e55 (2013).
105. Bowie, M. B. *et al.* Identification of a new intrinsically timed developmental checkpoint that reprograms key hematopoietic stem cell properties. *Proc. Natl. Acad. Sci.* **104**, 5878–5882 (2007).
106. Rufer, N. *et al.* Telomere Fluorescence Measurements in Granulocytes and T Lymphocyte Subsets Point to a High Turnover of Hematopoietic Stem Cells and Memory T Cells in Early Childhood. *J. Exp. Med.* **190**, 157–168 (1999).
107. Benz, C. *et al.* Hematopoietic Stem Cell Subtypes Expand Differentially during Development and Display Distinct Lymphopoietic Programs. *Cell Stem Cell* **10**, 273–283 (2012).
- Evidence that differentiation biases of HSC change over a lifetime.**
108. Geiger, H., de Haan, G. & Florian, M. C. The ageing haematopoietic stem cell compartment. *Nat. Rev. Immunol.* **13**, 376–389 (2013).

- 787 109. Young, K. *et al.* Progressive alterations in multipotent hematopoietic progenitors  
788 underlie lymphoid cell loss in aging. *J. Exp. Med.* jem.20160168 (2016).  
789 doi:10.1084/jem.20160168
- 790 110. Grover, A. *et al.* Single-cell RNA sequencing reveals molecular and functional platelet  
791 bias of aged haematopoietic stem cells. *Nat. Commun.* **7**, 11075 (2016).
- 792 111. Beerman, I. & Rossi, D. J. Epigenetic Control of Stem Cell Potential during  
793 Homeostasis, Aging, and Disease. *Cell Stem Cell* **16**, 613–625 (2015).
- 794 112. Flach, J. *et al.* Replication stress is a potent driver of functional decline in ageing  
795 haematopoietic stem cells. *Nature* **512**, 198–202 (2014).
- 796 113. Sun, D. *et al.* Epigenomic Profiling of Young and Aged HSCs Reveals Concerted  
797 Changes during Aging that Reinforce Self-Renewal. *Cell Stem Cell* **14**, 673–688 (2014).
- 798 114. Baryawno, N., Severe, N. & Scadden, D. T. Hematopoiesis: Reconciling Historic  
799 Controversies about the Niche. *Cell Stem Cell* **20**, 590–592 (2017).
- 800 115. Méndez-Ferrer, S., Lucas, D., Battista, M. & Frenette, P. S. Haematopoietic stem cell  
801 release is regulated by circadian oscillations. *Nature* **452**, 442–447 (2008).
- 802 116. Inra, C. N. *et al.* A perisinusoidal niche for extramedullary haematopoiesis in the  
803 spleen. *Nature advance online publication*, (2015).
- 804 117. Lefrançois, E. *et al.* The lung is a site of platelet biogenesis and a reservoir for  
805 haematopoietic progenitors. *Nature* **544**, 105–109 (2017).
- 806 118. Takizawa, H., Boettcher, S. & Manz, M. G. Demand-adapted regulation of early  
807 hematopoiesis in infection and inflammation. *Blood* **119**, 2991–3002 (2012).
- 808 119. Matatall, K. A. *et al.* Chronic Infection Depletes Hematopoietic Stem Cells through  
809 Stress-Induced Terminal Differentiation. *Cell Rep.* **17**, 2584–2595 (2016).

120. Hirche, C. *et al.* Systemic Virus Infections Differentially Modulate Cell Cycle State and Functionality of Long-Term Hematopoietic Stem Cells In Vivo. *Cell Rep.* **19**, 2345–2356 (2017).
121. Heidt, T. *et al.* Chronic variable stress activates hematopoietic stem cells. *Nat. Med.* **advance online publication**, (2014).
122. Ambrosi, T. H. *et al.* Adipocyte Accumulation in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and Bone Regeneration. *Cell Stem Cell* **0**, (2017).
123. Hérault, A. *et al.* Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. *Nature* **advance online publication**, (2017).
124. Naldini, L. Gene therapy returns to centre stage. *Nature* **526**, 351–360 (2015).
125. Cavazzana, M., Ribeil, J.-A., Lagresle-Peyrou, C. & André-Schmutz, I. Hematopoietic stem cell gene therapy: the point of view of the diseased bone marrow. *Stem Cells Dev.* (2016). doi:10.1089/scd.2016.0230
126. Steensma, D. P. The beginning of the end of the beginning in cancer genomics. *N. Engl. J. Med.* **368**, 2138–2140 (2013).
127. Chung, S. S. *et al.* Hematopoietic Stem Cell Origin of BRAFV600E Mutations in Hairy Cell Leukemia. *Sci. Transl. Med.* **6**, 238ra71-238ra71 (2014).
128. Horton, S. J. *et al.* Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. *Nat. Cell Biol.* **advance online publication**, (2017).
129. Eppert, K. *et al.* Stem cell gene expression programs influence clinical outcome in human leukemia. *Nat. Med.* **17**, 1086–1093 (2011).
130. Levine, J. H. *et al.* Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. *Cell* **162**, 184–197 (2015).

- 834 131. Cosgun, K. N. *et al.* Kit Regulates HSC Engraftment across the Human-Mouse Species  
835 Barrier. *Cell Stem Cell* **15**, 227–238 (2014).
- 836 132. Reinisch, A. *et al.* A humanized bone marrow ossicle xenotransplantation model  
837 enables improved engraftment of healthy and leukemic human hematopoietic cells.  
838 *Nat. Med.* **22**, 812–821 (2016).
- 839 133. Sontakke, P. *et al.* Modeling BCR-ABL and MLL-AF9 leukemia in a human bone  
840 marrow-like scaffold-based xenograft model. *Leukemia* **30**, 2064–2073 (2016).
- 841 134. Giustacchini, A. *et al.* Single-cell transcriptomics uncovers distinct molecular  
842 signatures of stem cells in chronic myeloid leukemia. *Nat. Med.* **advance online**  
843 **publication**, (2017).
- 844 135. Sugimura, R. *et al.* Haematopoietic stem and progenitor cells from human  
845 pluripotent stem cells. *Nature* **545**, 432–438 (2017).
- 846 136. Lis, R. *et al.* Conversion of adult endothelium to immunocompetent haematopoietic  
847 stem cells. *Nature* **545**, 439–445 (2017).
- 848 137. Wagner, J. E. *et al.* Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood  
849 Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft. *Cell Stem Cell* **18**,  
850 144–155 (2016).
- 851 138. Boitano, A. E. *et al.* Aryl Hydrocarbon Receptor Antagonists Promote the Expansion  
852 of Human Hematopoietic Stem Cells. *Science* **329**, 1345–1348 (2010).
- 853 139. Fares, I. *et al.* Pyrimidoindole derivatives are agonists of human hematopoietic stem  
854 cell self-renewal. *Science* **345**, 1509–1512 (2014).
- 855 140. Goodell, M. A., Brose, K., Paradis, G., Conner, A. S. & Mulligan, R. C. Isolation and  
856 functional properties of murine hematopoietic stem cells that are replicating in vivo. *J.*  
857 *Exp. Med.* **183**, 1797–1806 (1996).

141. Görgens, A. *et al.* Revision of the Human Hematopoietic Tree: Granulocyte Subtypes  
Derive from Distinct Hematopoietic Lineages. *Cell Rep.* doi:10.1016/j.celrep.2013.04.025
142. Dancey, J. T., Deubelbeiss, K. A., Harker, L. A. & Finch, C. A. Neutrophil kinetics in  
man. *J. Clin. Invest.* **58**, 705–715 (1976).
143. Hoogenkamp, M. *et al.* Early chromatin unfolding by RUNX1: a molecular explanation  
for differential requirements during specification versus maintenance of the  
hematopoietic gene expression program. *Blood* **114**, 299–309 (2009).
144. Hoppe, P. S. *et al.* Early myeloid lineage choice is not initiated by random PU.1 to  
GATA1 protein ratios. *Nature* **535**, 299–302 (2016).
145. Rieger, M. A., Hoppe, P. S., Smejkal, B. M., Eitelhuber, A. C. & Schroeder, T.  
Hematopoietic Cytokines Can Instruct Lineage Choice. *Science* **325**, 217–218 (2009).
146. Nishikawa, K. *et al.* Self-association of Gata1 enhances transcriptional activity in vivo  
in zebra fish embryos. *Mol. Cell. Biol.* **23**, 8295–8305 (2003).
147. Okuno, Y. *et al.* Potential autoregulation of transcription factor PU.1 by an upstream  
regulatory element. *Mol. Cell. Biol.* **25**, 2832–2845 (2005).
148. Pimanda, J. E. *et al.* Gata2, Fli1, and Scl form a recursively wired gene-regulatory  
circuit during early hematopoietic development. *Proc. Natl. Acad. Sci. U. S. A.* **104**,  
17692–17697 (2007).
149. Narula, J., Smith, A. M., Gottgens, B. & Igoshin, O. A. Modeling reveals bistability and  
low-pass filtering in the network module determining blood stem cell fate. *PLoS Comput.*  
*Biol.* **6**, e1000771 (2010).
150. Swiers, G., Patient, R. & Loose, M. Genetic regulatory networks programming  
hematopoietic stem cells and erythroid lineage specification. *Dev. Biol.* **294**, 525–540  
(2006).

Figure 1






Figure 2



# Figure 3

